Edition:
United States

PDL BioPharma Inc (PDLI.OQ)

PDLI.OQ on NASDAQ Stock Exchange Global Select Market

2.15USD
12:50pm EDT
Change (% chg)

$0.13 (+6.44%)
Prev Close
$2.02
Open
$2.06
Day's High
$2.15
Day's Low
$2.05
Volume
115,562
Avg. Vol
433,831
52-wk High
$3.84
52-wk Low
$1.93

Latest Key Developments (Source: Significant Developments)

PDL BioPharma announces settlement of Keytruda lawsuit with Merck
7:00am EDT 

April 24 (Reuters) - PDL BioPharma Inc ::PDL BioPharma announces settlement of Keytruda patent infringement lawsuit with Merck.PDL BioPharma Inc - under terms of agreement, Merck will pay company a one time, lump-sum payment of $19.5 million.PDL BioPharma Inc - company will grant Merck a fully paid-up, royalty free, non-exclusive license to certain of company's Queen et al.PDL BioPharma Inc - in addition, parties agreed to dismiss all claims in relevant legal proceedings.PDL BioPharma Inc - as a result of settlement, expect to recognize $19.5 million in license revenue for q2 ending june 30, 2017.  Full Article

Pdl Biopharma qtrly loss per share $0.06
Wednesday, 1 Mar 2017 04:02pm EST 

Pdl Biopharma Inc : Board of directors has authorized repurchase of up to $30 million of company's common stock through march 2018 . Pdl biopharma announces fourth quarter and year end 2016 financial results . Q4 revenue $66.5 million .Qtrly loss per share $0.06.  Full Article

PDL Biopharma announces $30 mln share repurchase program
Wednesday, 1 Mar 2017 07:00am EST 

PDL Biopharma Inc : PDL Biopharma Inc - company's board of directors has authorized repurchase of up to $30 million of company's common stock through March 2018 .PDL Biopharma announces $30 million share repurchase program.  Full Article

PDL BioPharma says board authorized repurchase of up to $30 mln of stock through March 2018
Wednesday, 1 Mar 2017 06:35am EST 

Pdl Biopharma Inc :Pdl biopharma inc- company's board of directors has authorized repurchase of up to $30 million of company's common stock through march 2018.  Full Article

PDL BioPharma issues $150.0 mln of 2.75 pct convertible senior notes
Tuesday, 22 Nov 2016 02:44pm EST 

PDL BioPharma Inc - : 2021 notes bear interest at a rate of 2.75 pct per year .PDL BioPharma issues $150.0 million of 2.75 pct convertible senior notes due 2021.  Full Article

PDL BioPharma qtrly earnings per share $0.08
Thursday, 3 Nov 2016 04:02pm EDT 

PDL BioPharma Inc - : Qtrly earnings per share $0.08 . PDL BioPharma announces third quarter 2016 financial results .Q3 revenue $53.6 million.  Full Article

PDL Biopharma reports Q2 adjusted earnings per share $0.09
Thursday, 4 Aug 2016 04:05pm EDT 

PDL Biopharma Inc : Q2 revenue $21 million . PDL Biopharma announces second quarter 2016 financial results . On august 3, 2016, pdl board of directors decided to eliminate quarterly cash dividend payment . Q2 non-gaap earnings per share $0.09 .Q2 gaap earnings per share $0.03.  Full Article

PDL Biopharma dismisses quarterly cash dividend
Thursday, 4 Aug 2016 04:02pm EDT 

PDL Biopharma Inc :Board of directors has decided to eliminate its quarterly cash dividend.  Full Article

PDL Biopharma files for mixed shelf of up to $250 mln
Friday, 10 Jun 2016 05:17pm EDT 

PDL Biopharma Inc :Files for mixed shelf of up to $250 million - SEC filing.  Full Article

PDL Biopharma says agreed to equity investment in Noden Pharma
Tuesday, 24 May 2016 04:02pm EDT 

PDL Biopharma Inc : Transaction expected to be immediately accretive . PDL expects to make equity contributions to Noden totaling approximately $107 million in first year of transaction . Noden is also expected to obtain debt financing in conjunction with PDL equity investment. . PDL will have three of five seats on Noden's board of directors .PDL Biopharma commits to equity investment in Noden Pharma for the acquisition of Tekturna (aliskiren) and Tekturna HCT (aliskiren and hydrochlorothiazide).  Full Article

More From Around the Web

BRIEF-PDL BioPharma announces settlement of Keytruda lawsuit with Merck

* PDL BioPharma announces settlement of Keytruda patent infringement lawsuit with Merck